Not Yet RecruitingNot Applicable

Methamphetamine, PrEP, and Intersectional Stigma Study

20 participantsStarted 2026-04-15

Plain-language summary

The goal of this clinical trail is to test the developed eMPrISe study in HIV-negative, adult, Latino men who have sex with men (MSM) who use non-injection substances. The main questions it aims to answer are: * Can participation in the developed eMPrISe study reduce methamphetamine ('meth') use risk? * Can participation in the developed eMPrISe study improve preexposure prophylaxis (PrEP) cascade progression? Participants will participate in 12 weekly modules that: (1) build critical thinking skills, (2) identify and discuss the link between oppression and harmful behaviors, (3) take action, (4) voice and validate feelings and experiences, and (5) share knowledge and resources.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18+ years of age * cisgender male * self-identify as Latino or Hispanic * fluent in English or Spanish * any sexual activity with men in the past 12 months * HIV-negative * moderate methamphetamine use risk (as determined by the the ASSIST assessment) * experience of intersectional stigma within their social network in the past 12 months * willing to provide written informed consent Exclusion Criteria: * N/A

What they're measuring

Methamphetamine use risk

Timeframe: 3 Months

PrEP cascade progression

Timeframe: 3 Months

Trial details

NCT IDNCT05784467

SponsorArizona State University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08-01

Contact for this trial

Angel B Algarin, PhD, MPH

(602) 496-0845 angel.algarin@asu.edu

View on ClinicalTrials.gov More Methamphetamine Abuse trials